920966-13-8 Usage
General Description
1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-chloro- is a chemical compound with the molecular formula C10H7ClN4O. It is a derivative of pyrrolopyridine and contains a chloro substituent at the fourth position on the pyridine ring. 1H-Pyrrolo[2,3-b]pyridine-5-carboxamide, 4-chloro- has potential pharmacological activities and is being studied for its potential use in medicinal and pharmaceutical applications. Its structure and properties make it of interest to researchers looking to develop new drugs or understand the mechanism of action of existing pharmaceuticals. As a chloro derivative, it may have unique interactions with biological targets and could exhibit different properties compared to other related compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 920966-13-8 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,0,9,6 and 6 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 920966-13:
(8*9)+(7*2)+(6*0)+(5*9)+(4*6)+(3*6)+(2*1)+(1*3)=178
178 % 10 = 8
So 920966-13-8 is a valid CAS Registry Number.
920966-13-8Relevant articles and documents
JANUS KINASE (JAK) FAMILY INHIBITOR, PREPARATION OF SAME, AND APPLICATIONS THEREOF
-
, (2021/12/18)
A 7-azaindole derivative having the structure of formula (I), a pharmaceutical composition containing the compound of formula (I), and uses of the compound in preparing a medicament for preventing or treating Janus kinase (JAK) family-related diseases, specifically, uses in preventing or treating inflammatory diseases related to protein tyrosine kinase.
SUBSTITUTED HETEROARYL COMPOUNDS AND METHODS OF USE
-
, (2018/10/19)
The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof. They are useful in preventing, managing, treating or lessening the severity of a protein kinase-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.